Neuland Laboratories Limited Earnings Summary — Q4 FY2026
Neuland Laboratories Delivers Record Quarterly Performance Driven by High-Margin CMS Segment
Key Takeaways
- Revenue surged to a record INR 776 crore in Q4 FY2026, representing a massive 136% YoY growth.
- Operating Profit Margin (OPM) reached a multi-year high of 40%, reflecting a structural shift toward high-margin CMS projects.
- Net Profit multiplied more than 7x YoY, jumping from INR 28 crore in the prior year's same quarter to INR 213 crore.
- The company is completing a significant capex cycle with INR 397 crore invested in FY2026, aimed at expanding capacity for specialty molecules.
- CMS (Custom Manufacturing Solutions) continues to be the primary engine of growth, driving significant operating leverage.
- Borrowings increased to INR 301 crore to support aggressive capacity expansion and working capital requirements.
- The transition from a volume-player to a value-compounder is evidenced by the profit growth significantly outpacing sales growth.
Management Guidance
Management remains focused on pivoting Neuland toward complex chemistry and late-stage clinical projects to drive sustainable high-alpha expansion.
Sentiment Shift
Improving
Outlook
The outlook is exceptionally strong as the company moves up the value chain with global innovator clients, though quarterly results may remain lumpy due to the nature of CMS project timelines. Significant new capacity (CWIP at INR 210Cr) is poised to come online.
← Back to Neuland Laboratories Limited AI analysis
Unlock the full report
Deep-dive sections, financial charts, AI chat and PDF export are available with Premium.
This summary is AI-generated from Neuland Laboratories Limited's latest annual report and public disclosures. It is for informational purposes only and is not investment advice.